Role of HIF-1 in Iron Regulation: Potential Therapeutic Strategy for Neurodegenerative Disorders

Author(s): Donna W. Lee, Julie K. Andersen

Journal Name: Current Molecular Medicine

Volume 6 , Issue 8 , 2006

Become EABM
Become Reviewer


A disruption in optimal iron levels within different brain regions has been demonstrated in several neurodegenerative disorders. Although iron is an essential element that is required for many processes in the human body, an excess can lead to the generation of free radicals that can damage cells. Iron levels are therefore stringently regulated within cells by a host of regulatory proteins that keep iron levels in check. The iron regulatory proteins (IRPs) have the ability to sense and control the level of intracellular iron by binding to iron responsive elements (IREs) of several genes encoding key proteins such as the transferrin receptor (TfR) and ferritin. Concurrently, the hypoxia-inducible factor (HIF) has also been shown in previous studies to regulate intracellular iron by binding to HIFresponsive elements (HREs) that are located within the genes of iron-related proteins such as TfR and heme oxygenase-1 (HO-1). This review will focus on the interactions between the IRP/IRE and HIF/HRE systems and how cells utilize these intricate networks to regulate intracellular iron levels. Additionally, since iron chelation has been suggested to be a therapeutic treatment for disorders such as Parkinsons and Alzheimers disease, understanding the exact mechanisms by which iron acts to cause disease and how the brain would be impacted by iron chelation could potentially give us novel insights into new therapies directed towards preventing or slowing neuronal cell loss associated with these disorders.

Keywords: HIF-mediated transcription, Ferritin, GSH depletion, VEGF, von Hippel-Lindau (vHL)

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2006
Page: [883 - 893]
Pages: 11
DOI: 10.2174/156652406779010849
Price: $65

Article Metrics

PDF: 9